Ariana Pelosci | Authors


Survival Benefit in Transplant-Ineligible Multiple Myeloma Seen With Frontline Vs Second Line Use of Daratumumab Combos

December 11, 2021

Compared to those who waited and received second line daratumumab-based regimens for transplant-ineligible newly diagnosed multiple myeloma, patients receiving daratumumab, lenalidomide, and dexamethasone in the first line saw better overall survival.